Tau aggregation in the hippocampal formation: an ageing or a pathological process?
- PMID: 12470843
- DOI: 10.1016/s0531-5565(02)00141-9
Tau aggregation in the hippocampal formation: an ageing or a pathological process?
Abstract
Tauopathy is a concept to describe different genetic or metabolic dysfunctions of tau proteins that generate most of the known dementing disorders. Tauopathy is a degenerating process that also affects the entorhinal formation, and then the hippocampal formation in ageing. In Alzheimer's disease (AD), a disease due to APP dysfunction, a similar tauopathy process in observed in neocortical areas, well correlated to cognitive impairment. One important gap of knowledge is the relationship between tauopathy in the hippocampal formation, ageing, AD, and cognitive impairment. Here we show that the multidisciplinary analysis of numerous brains from non-demented and demented patients suggests the following observations: tauopathy of the hippocampal formation in humans is age-related but not an age-dependent process, also independent of AD, but amplified by APP dysfunctions. Tauopathy in the entorhinal and hippocampal formation could be another type of pathological dysfunction of tau proteins, and a therapeutic target to delay AD. Relevant animal models are desperately needed to address this issue.
Similar articles
-
The GABAergic septohippocampal connection is impaired in a mouse model of tauopathy.Neurobiol Aging. 2017 Jan;49:40-51. doi: 10.1016/j.neurobiolaging.2016.09.006. Epub 2016 Sep 15. Neurobiol Aging. 2017. PMID: 27743524
-
A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.Exp Neurol. 2008 Jul;212(1):71-84. doi: 10.1016/j.expneurol.2008.03.007. Epub 2008 Mar 21. Exp Neurol. 2008. PMID: 18490011
-
The natural and molecular history of Alzheimer's disease.J Alzheimers Dis. 2006;9(3 Suppl):187-94. doi: 10.3233/jad-2006-9s322. J Alzheimers Dis. 2006. PMID: 16914858
-
[Drug development for tauopathy and Alzheimer's disease].Nihon Shinkei Seishin Yakurigaku Zasshi. 2010 Aug;30(4):177-80. Nihon Shinkei Seishin Yakurigaku Zasshi. 2010. PMID: 20857696 Review. Japanese.
-
[Tauopathy and Alzheimer disease: a full degenerating process].Psychol Neuropsychiatr Vieil. 2006 Dec;4(4):261-73. Psychol Neuropsychiatr Vieil. 2006. PMID: 17194646 Review. French.
Cited by
-
Novel Protein Kinase Inhibitors Related to Tau Pathology Modulate Tau Protein-Self Interaction Using a Luciferase Complementation Assay.Molecules. 2018 Sep 12;23(9):2335. doi: 10.3390/molecules23092335. Molecules. 2018. PMID: 30213139 Free PMC article.
-
In Vivo Detection of Amyloid Plaques by Gadolinium-Stained MRI Can Be Used to Demonstrate the Efficacy of an Anti-amyloid Immunotherapy.Front Aging Neurosci. 2016 Mar 22;8:55. doi: 10.3389/fnagi.2016.00055. eCollection 2016. Front Aging Neurosci. 2016. PMID: 27047372 Free PMC article.
-
Dementia spectrum disorders: lessons learnt from decades with PET research.J Neural Transm (Vienna). 2019 Mar;126(3):233-251. doi: 10.1007/s00702-019-01975-4. Epub 2019 Feb 14. J Neural Transm (Vienna). 2019. PMID: 30762136 Free PMC article. Review.
-
Age, Sex, and APOE ε4 Effects on Memory, Brain Structure, and β-Amyloid Across the Adult Life Span.JAMA Neurol. 2015 May;72(5):511-9. doi: 10.1001/jamaneurol.2014.4821. JAMA Neurol. 2015. PMID: 25775353 Free PMC article.
-
Role of β-Amyloidosis and Neurodegeneration in Subsequent Imaging Changes in Mild Cognitive Impairment.JAMA Neurol. 2015 Dec;72(12):1475-83. doi: 10.1001/jamaneurol.2015.2323. JAMA Neurol. 2015. PMID: 26437123 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous